Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6BCS

LilrB2 D1D2 domains complexed with benzamidine

Summary for 6BCS
Entry DOI10.2210/pdb6bcs/pdb
DescriptorLeukocyte immunoglobulin-like receptor subfamily B member 2, BENZAMIDINE, CHLORIDE ION, ... (5 entities in total)
Functional Keywordsreceptor, ig like domains, immune system
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight22773.67
Authors
Cao, Q.,Sawaya, M.R.,Eisenberg, D.S. (deposition date: 2017-10-20, release date: 2018-09-05, Last modification date: 2024-10-23)
Primary citationCao, Q.,Shin, W.S.,Chan, H.,Vuong, C.K.,Dubois, B.,Li, B.,Murray, K.A.,Sawaya, M.R.,Feigon, J.,Black, D.L.,Eisenberg, D.S.,Jiang, L.
Inhibiting amyloid-beta cytotoxicity through its interaction with the cell surface receptor LilrB2 by structure-based design.
Nat Chem, 10:1213-1221, 2018
Cited by
PubMed Abstract: Inhibiting the interaction between amyloid-β (Aβ) and a neuronal cell surface receptor, LilrB2, has been suggested as a potential route for treating Alzheimer's disease. Supporting this approach, Alzheimer's-like symptoms are reduced in mouse models following genetic depletion of the LilrB2 homologue. In its pathogenic, oligomeric state, Aβ binds to LilrB2, triggering a pathway to synaptic loss. Here we identify the LilrB2 binding moieties of Aβ (KLVFFA) and identify its binding site on LilrB2 from a crystal structure of LilrB2 immunoglobulin domains D1D2 complexed to small molecules that mimic phenylalanine residues. In this structure, we observed two pockets that can accommodate the phenylalanine side chains of KLVFFA. These pockets were confirmed to be KLVFFA binding sites by mutagenesis. Rosetta docking revealed a plausible geometry for the Aβ-LilrB2 complex and assisted with the structure-guided selection of small molecule inhibitors. These molecules inhibit Aβ-LilrB2 interactions in vitro and on the cell surface and reduce Aβ cytotoxicity, which suggests these inhibitors are potential therapeutic leads against Alzheimer's disease.
PubMed: 30297750
DOI: 10.1038/s41557-018-0147-z
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

237735

건을2025-06-18부터공개중

PDB statisticsPDBj update infoContact PDBjnumon